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Introduction: Glucagon-like peptide-1 receptor agonists, a new class of anti-diabetic drugs, are widely used in the
treatment of type 2 diabetes. However, the effect of glucagon-like peptide-1 receptor agonists on the treatment of
preoperative weight loss in obese type 2 diabetic patients has not been reported.
Case presentation: A 38-year-old Taiwanese woman presented to our hospital with morbid obesity and type 2
diabetes mellitus. Bariatric surgery was recommended by a general surgery specialist. Weight loss before surgery
was recommended to reduce the frequency of surgical complications. In addition to diet control with lifestyle
modifications, pharmacological treatment with metformin and glucagon-like peptide-1 receptor agonists was
administered. Fourteen months of treatment reduced her hemoglobin A1c level from 7.4 to 5.5% and reduced
her body weight by 21.2kg.
Conclusions: One year of diet control with lifestyle modifications and pharmacological treatment with
glucagon-like peptide-1 receptor agonists and metformin markedly decreased hemoglobin A1c levels and
resulted in effective and substantial weight loss in a morbidly obese patient with dysregulated diabetes during
the preoperative period.
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Bariatric or metabolic surgery can rapidly improve
glycemic control and cardiovascular risk factors in severely
obese patients with type 2 diabetes [1-3]. Growing evi-
dence has revealed that preoperative weight loss before
surgery plays a crucial role in the preparation of morbidly
obese patients during bariatric surgery [4-6]. Preoperative
weight loss may be associated with a reduced risk of
surgical complications in bariatric surgery. However, the
optimal method of preoperative weight loss remains
controversial; these methods include a low calorie or very
low calorie diet or the placement of an intragastric bal-
loon. Recently, glucagon-like peptide-1 (GLP-1) receptor* Correspondence: doc10383@gmail.com
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unless otherwise stated.agonists, such as exenatide and liraglutide, can efficiently
reduce blood glucose levels, enhance satiety and reduce
energy intake through centrally mediated mechanisms
[7,8]. These GLP-1 receptor agonists are now used in-
creasingly in the treatment of obesity-related type 2 dia-
betes, but the effects of these drugs in preoperative weight
loss are not known. We report the case of a patient with
type 2 diabetes and severe obesity who had an excellent
therapeutic response to diet control with lifestyle mo-
difications and GLP-1 receptor agonists, which included
significant improvements in weight and glycemic control.Case presentation
A 38-year-old Taiwanese woman, with a past history
(more than five years) of hypertension, presented to our
outpatient clinic in May 2012 with several months of dete-
riorated shortness of breath and dyspnea upon exertion.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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69.9kg/m2, and her fasting glucose level was 132mg/dl.
Under the diagnosis of morbid obesity and suspected
diabetes mellitus, she was admitted to our ward. She re-
ported no history of gestational diabetes mellitus, with a
baby birth weight of approximately 3600gm. However, her
mother has a family history of type 2 diabetes mellitus.
Upon admission, her body temperature was 36.6°C,
her pulse rate was 101/min, her respiratory rate was
20/min, and her blood pressure was 146/89mmHg.
Physical examinations revealed hyperpigmentation over
the neck and axillary regions. During hospitalization, her
hemoglobin A1C (HbA1c) was 7.4%. Her other endo-
crinologic blood examinations, such as free T4, human
growth hormone, cortisol, 24-hours urine free cortisol,
adrenocorticotropic hormone (ACTH), follicle-stimulating
hormone (FSH), luteinizing hormone (LH), prolactin,
estradiol, progesterone, testosterone and dehydroepian-
drosterone sulfate (DHEA-S) were within normal limits,
however, her thyroid-stimulating hormone (TSH) was
mildly elevated (5.81μIU/ml).
Bariatric surgery was recommended by a general surgery
(GS) specialist, however, she was warned about the high
risk of complications associated with the surgery. Diet
control with lifestyle modifications and pharmacological
treatment for weight loss before surgery were recom-
mended to reduce the chance of surgical complications.
We consulted dietitians and a high fiber diabetic full diet
with a calorie restriction of 1800kcal/day was recommen-
ded. In addition to diet control with lifestyle modifications,
pharmacological treatment with metformin (1g/day) and a
GLP-1 receptor agonist (exenatide 20mg/day via subcuta-
neous injection) were administered. Following the initi-
ation of metformin and exenatide, she experienced weight
loss, which continued throughout the therapy until May
2013. She reported poor compliance of exenatide at a twice
daily usage, therefore we replaced exenatide with lira-
glutide (1.2mg/day via subcutaneous injection). Fourteen
months of treatment reduced her HbA1c level to 5.5% and
reduced her body weight by 21.2kg (Figure 1). She reported
no problems with gastrointestinal distress or hypoglycemia
and noted a slight decrease in appetite. She is currently
under regular GS outpatient clinic follow-up and bariatric
surgery has been arranged.
Discussion
We reported that one year of diet control with lifestyle
modifications and GLP-1 receptor agonist treatment
markedly decreased HbA1c levels and resulted in a sub-
stantial weight loss in a severely obese patient with dysreg-
ulated diabetes. To the best of our knowledge, this is the
first clinical evidence supporting the use of GLP-1 recep-
tor agonists on the treatment of preoperative weight loss
in obese type 2 diabetic patients.Bariatric surgery may be considered for adults with a
BMI of ≧35kg/m2 and type 2 diabetes, especially if the
diabetes or associated comorbidities are difficult to control
with lifestyle modifications and pharmacological therapy
[9]. Recently, the topic of preoperative weight loss before
bariatric surgery has garnered increasing attention. Several
studies have demonstrated that preoperative weight loss
resulted in decreased operative time, perioperative com-
plications and greater total postoperative weight loss.
Livhits et al. [5] declared that preoperative weight loss
immediately before bariatric surgery appears to improve
the total postoperative weight loss and decrease the op-
erative time. A modest decrease of 10% of excess body
weight will improve a patient’s respiratory mechanics
and decrease both cardiovascular and thromboembolic
risk factors, chronic pro-inflammatory status and serum
glucose concentrations [10,11]. In addition to the poten-
tial to improve global patient risk factors, preoperative
weight loss also decreases intra-abdominal fat stores.
The proposed mechanism involves the shrinkage of
visceral adiposity and intrahepatic fat [12].
The methods of preoperative weight loss differed among
reported studies but generally included a nutritional com-
ponent under the direction of a registered dietician and an
exercise plan. Several studies demonstrated a positive
effect of preoperative weight loss with a low calorie liquid
diet, and most studies included dietary logs and nutri-
tional education. A very low energy diet instituted before
bariatric surgery has been shown to decrease the liver
volume and visceral and subcutaneous adipose tissue
in proportion to the reduction in body weight [6]. A
successful preoperative weight loss program will likely
contain both exercise and a nutritional component, with
the latter providing specific dietary instructions and spe-
cialized counseling.
With the exception of diet control with lifestyle modifi-
cations, many review articles reaffirm the weight benefits
of metformin alone or in combination with other anti-
diabetic agents that are not associated with weight gain
for the treatment of diabetes and body weight loss [9].
GLP-1 receptor agonists, a new class of anti-diabetic
drugs, are widely used in the treatment of type 2 diabetes
[7]. GLP-1 receptor agonists stimulate glucose-induced
insulin secretion, inhibit glucagon secretion and reduce
gastrointestinal motility, which reduces appetite and food
intake [8]. As shown in previous studies, exogenously
administered GLP-1 receptor agonists have a therapeutic
role in restoring beneficial effects to decrease HbA1c by
approximately 1% and to promote weight loss of 2 to 3kg
over six months [13]. Randomized placebo-controlled tri-
als using exenatide in patients with type 2 diabetes have
shown a mean weight reduction of between 2 and 3kg at
30 weeks, and nearly 5kg (5% excess weight loss (%EWL)
from baseline) in open-label extension studies of up to
Figure 1 Course of treatment graph showing the corresponding effect on weight and HbA1c level. The duration of treatment with diet
control, lifestyle modifications and pharmacological agents in our patient is represented by the length of each box relative to the time period on
the x-axis. Changes in HbA1c are shown by the black circle line plotted against the y-axis (right), and changes in weight are shown by the blue
rhombus line plotted against the y-axis (left). Significant improvement in glycemic control and sustained weight loss after metformin and
exenatide is shown.
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weight reduction from baseline using diet control with
lifestyle modifications, metformin and GLP-1 receptor
agonists, which was a better result than the published
clinical trials, and this benefit was sustained over the
following year. Our treatment also efficiently reduced
blood glucose levels and no episode of hypoglycemia has
occurred since the treatment.
Conclusions
As mentioned above, preoperative weight loss appears to
be associated with greater weight loss postoperatively
and is associated with fewer complications after gastric
bypass surgery. Different methods, such as a low or very
low calorie diet or an intragastric balloon, were used for
preoperative weight loss just before bariatric surgery. In
this study, diet control with lifestyle modifications and
pharmacologic therapy with GLP-1 receptor agonists
resulted in clinically relevant beneficial effects on body
weight loss and blood sugar control before bariatric sur-
gery. Therefore, in addition to diet control and lifestyle
modifications, GLP-1 receptor agonists would appear to
be an important therapeutic option in a morbidly obese
patient with type 2 diabetes before undergoing bariat-
ric surgery. Randomized controlled clinical trials of
GLP-1 receptor agonists as preoperative weight-reducing
agents in severely obese patients with type 2 diabetes are
warranted.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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